BEVERLY HILLS, Calif.— The liquid is dark red, a mixture of fat and blood, and Dr. Mark Berman pumps it out of the patient's backside. The number of stem-cell clinics across the United States has surged from a handful in 2010 to more than 170 today, according to figures compiled by The Associated Press.» Read More
CNBC's Bertha Coombs reports on which sectors and stocks are impacted by Obamacare, and the FMHR traders share their top health care stock picks.
Barbara Ryan, FTI Consulting managing director, analyzes the biotech sector and reveals which companies are on the forefront of therapies worth investing in.
Steven St. Peter, Aratana Therapeutics president & CEO, discusses the need for pet medical pharmaceuticals and the market for pet insurance.
CNBC's Sheila Dharmarajan reports on what factors contribute to the biotech sector outperforming this year.
As Bristol-Myers Squibb prepares to report its Q4 earnings on Friday, CNBC's Morgan Brennan and Seamus Fernandez, Leerink Partners managing director & pharma analyst, discuss if now is the time to invest in the biotech.
Mark Schoenebaum, ISI Group analyst, breaks down the red hot biotech sector and explains why Gilead Sciences is his best play.
Dan Fitzpatrick, StockmarketMentor.com president & technical analyst, takes a look at the charts to get a technical read on Twitter. Also a look at why Fitzpatrick likes the biotech sector.
Alexandria Real Estate Equities founder, chairman and CEO Joel Marcus discuss its firm's success, and how rising yields impact its dividend.
Alexandria Real Estate Equities founder, chairman and CEO Joel Marcus discuss real estate demand in the biotech industry.
Perrigo CEO Joseph Papa provides insight on the current flu season, and how it plans on getting its name better known.
Perrigo CEO Joseph Papa discusses how its new headquarters in Ireland will impact its tax structure, and whether the company will add a dividend.
Biogen Idec CEO George Scangos discusses the busy year ahead for the company, including the EU launch of Tecfidera and when a dividend will be offered.
The Supreme Court upheld Monsanto's biotech seed patents on Monday, dealing a blow to organic farmers and critics of the company.
The outlook for biotech is "wonderful," explains Sam Isaly, Orbimed Advisors managing partner.
Shares of Intercept Pharmaceuticals are up more than 560 percent this week alone. Akiva Felt, Oppenheimer senior analyst, shares his optimistic view for the company.
Daryl Liew, Head Of Portfolio Management of REYL Singapore advises investors to look past short-term volatilities in the country's economy after Q4 GDP data missed expectations
CNBC's Seema Mody reports the biotech index has hit an all-time high in the Nasdaq.
Johnson & Johnson and its subsidiaries were accused of promoting powerful psychiatric drugs for unapproved uses in children, seniors and disabled patients.
CNBC's Seema Mody reports on the biggest movers in the Nasdaq including social media stocks like Facebook up 5 percent.
Francois Nader, NPS Pharmaceuticals president & CEO, discusses its lead product Gattex for "short bowel syndrome," the potential for Netpara and the solid performance of its stock.